Logo image
A step forward for an attenuated blood-stage malaria vaccine
Journal article   Open access   Peer reviewed

A step forward for an attenuated blood-stage malaria vaccine

James M. Burns
BMC medicine, v 16(1), pp 204-204
09 Nov 2018
PMID: 30409141
url
https://doi.org/10.1186/s12916-018-1197-1View
Published, Version of Record (VoR)CC BY V4.0 Open

Abstract

Attenuated vaccines Blood-stage parasites Malaria Plasmodium falciparum
Efforts to develop an effective malaria vaccine have encountered multiple challenges, and have had limited success to date. As the need remains urgent, novel approaches must be explored. One concept that has gained attention uses whole malaria parasites. Building on preclinical studies in animal models, Stanisic et al. describe the development of a vaccine based on chemically attenuated Plasmodium falciparum blood-stage parasites, with an evaluation of safety and immunogenicity in malaria-naïve human subjects. The vaccine was shown to be safe, well tolerated, and capable of priming antigen-specific T cells. This work, and the completion of an initial clinical trial in human subjects, represents a significant advance. While the path forward for this attenuated vaccine remains challenging, these initial findings are encouraging. Importantly, the results provide the foundation and framework for testing modified immunization protocols, and designing subsequent clinical trials to further evaluate safety, test for enhanced immunogenicity, and ultimately measure protective efficacy. Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1173-9

Metrics

13 Record Views
3 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Immunology
Logo image